#United States #New York #ALS #NeuroSense #PrimeC

NeuroSense Therapeutics to Attend the Annual ROTH Healthcare Opportunities Conference

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-stage clinical biotechnology firm committed to developing treatments for neurodegenerative diseases, has announced its participation in the 5th Annual ROTH Healthcare Opportunities Conference. This significant event will take place on September 29, 2026, at The Metropolitan Club in New York City.

At the forefront of the conference, Chief Financial Officer Or Eisenberg will engage in one-on-one and small-group meetings with institutional investors, providing insights into the company's progress and future directions. The discussions will particularly focus on NeuroSense's lead drug candidate, PrimeC, aimed at treating amyotrophic lateral sclerosis (ALS).

NeuroSense is dedicated to developing innovative therapies that can modify the progression of ALS and other severe neurodegenerative conditions. The company's flagship product, PrimeC, represents a novel oral treatment designed to address multiple biological pathways associated with neurodegeneration, including neuroinflammation and oxidative stress.

Recent Progress and Clinical Trials

NeuroSense has made notable advancements in its clinical studies, having published results from its Phase 2b PARADIGM study in ALS in JAMA Neurology. This research indicated a significant slowing of functional decline in ALS patients when treated with PrimeC compared to those on placebo. Additionally, the company reported positive changes in biomarkers linked to ALS, affirming the multi-target mechanism of PrimeC’s action.

Upcoming Phase 3 Trials

An encouraging development is the recent FDA clearance for NeuroSense to initiate its pivotal Phase 3 PARAGON trial. The company is collaborating closely with the FDA to optimize the design of this critical study. The timely advancement of PrimeC towards regulatory approval in markets like Canada and the U.S. is paramount for the company.

Significance of the ROTH Conference

The 5th Annual ROTH Healthcare Opportunities Conference serves as a vital platform for biotechnology companies like NeuroSense to interact with potential investors and stakeholders. By presenting their latest findings and strategies, they seek to garner support and funding essential for their clinical trials and research initiatives.

This event not only provides a spotlight on NeuroSense's innovative approach to tackling diseases such as ALS but also raises awareness about the pressing need for advancements in this space. With over 5,000 individuals diagnosed with ALS annually in the U.S. alone, the implications of NeuroSense's work are profound, particularly as the number of people living with ALS is expected to grow significantly over the next two decades.

About NeuroSense and PrimeC

NeuroSense Therapeutics is at the cutting edge of developing novel treatments for challenging medical conditions such as ALS and Alzheimer’s disease. PrimeC, the company’s primary drug candidate, is a unique combination of FDA-approved medications — ciprofloxacin and celecoxib — formulated to inhibit mechanisms crucial to neuron degeneration and inflammation.

With a mission to transform the landscape of neurodegenerative disease treatment, NeuroSense aims to bring hope to countless patients and families affected by these devastating conditions.

To stay updated on NeuroSense’s journey toward regulatory approval and further clinical developments, interested parties can visit their official website and follow their social media channels.

Conclusion

The upcoming participation of NeuroSense Therapeutics in the ROTH Healthcare Opportunities Conference marks an important milestone in its quest to develop effective treatments for neurodegenerative diseases. The attention from institutional investors and the medical community at large could catalyze significant progress in the development and approval of PrimeC, potentially leading to a brighter future for patients suffering from ALS and other related ailments.